AI Market Mood: Stock Dashboard
ZBIO
Fundamental
Company: Zenas Biopharma Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -4.53
Insider Own: 59.14%
Shs Outstand: 42.21M
Perf Week: -10.94%
Market Cap: 1.94B
Forward P/E: -
EPS next Y: -4.26
Insider Trans: 3.19%
Shs Float: 21.93M
Perf Month: -2.69%
Enterprise Value: 1.65B
PEG: -
EPS next Q: -0.60
Inst Own: 31.11%
Short Float: 22.16%
Perf Quarter: 90.77%
Income: -189.90M
P/S: 129.37
EPS this Y: 65.99%
Inst Trans: 2.20%
Short Ratio: 11.56
Perf Half Y: 281.73%
Sales: 15.00M
P/B: 7.77
EPS next Y Percentage: -5.38%
ROA: -52.35%
Short Interest: 4.86M
Perf YTD: 341.39%
Book/sh: 4.65
P/C: 6.67
EPS next 5Y: 31.91%
ROE: -68.33%
52W High: 41.50 -12.89%
Perf Year: 281.33%
Cash/sh: 5.42
P/FCF: -
EPS past 3/5Y: -9.85% -
ROIC: -96.59%
52W Low: 5.83 520.07%
Perf 3Y: -
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: 99.47%
Volatility W: 15.61%
Volatility M: 9.38%
Perf 5Y: -
Dividend TTM: -
EV/Sales: 110.03
EPS Y/Y TTM: -38.04%
Oper. Margin: -1304.64%
ATR (14): 3.35
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 5.66
Sales Y/Y TTM: -70.00%
Profit Margin: -1265.99%
RSI (14): 50.39
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 5.66
EPS Q/Q: -32.20%
SMA20: -3.98%
Beta: -1.22
Target Price: 47.75
Payout: -
Debt/Eq: 0.00
Sales Q/Q: -
SMA50: 8.90%
Rel Volume: 3.31
Prev Close: 35.07
Employees: 130
LT Debt/Eq: 0.00
Earnings: Nov 12 BMO
SMA200: 100.46%
Avg Volume: 420.35K
Price: 36.15
IPO: Sep 13, 2024
Option/Short: Yes / Yes
EPS/Sales Surpr.: -17.57% -100.00%
Trades:
Volume: 1,390,263
Change: 3.08%
Technical:
Latest News:
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 million valuation in US IPO somewhat bullish
ZBIO
Summary: Zenas BioPharma aims for a valuation of up to $689.7 million in its U.S. IPO, backed by Bristol-Myers Squibb and targeting to raise $211.7 million by offering 11.76 million shares.
Full article2024-09-06T12:28:43Z